A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies

    Not Recruiting
  • End date
    Sep 20, 2026
  • participants needed
  • sponsor
    Gilead Sciences
Updated on 22 September 2023


The primary objectives of this study are to evaluate the safety, tolerability and to determine the recommended Phase 2 dose (RP2D) of magrolimab (Mag) in combination with the anti-leukemia therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants with acute myeloid leukemia (AML), to evaluate the efficacy of magrolimab in combination with the anti-leukemia therapies as determined by the rate of complete remission (CR) (Phase 2 Cohorts 1 and 2), and/or complete remission with incomplete hematologic recovery (CRi) (CR/CRi) (Phase 2 Cohort 2) and to evaluate the efficacy of magrolimab in combination with anti-leukemia therapy CC-486 as determined by the minimal residual disease (MRD) negative CR rate (Phase 2 Cohort 3).


This study consists of 3 safety run-in cohorts;

  • Safety Run-in Cohort 1 (1L Unfit AML Mag + Ven + Aza)
  • Safety Run-in Cohort 2 (R/R AML Mag + MEC)
  • Safety Run-in Cohort 3 (Post-chemo Maintenance Mag + CC-486)

Participants will receive treatment at the assigned dose level for at least 4 cycles in the Safety Run-in cohorts, after which they may continue at the assigned dose level or switch to the RP2D upon agreement between the investigator and the sponsor. After completion of each safety run-in cohort and identification of the RP2D for that cohort, participants may be enrolled into the corresponding Phase 2 cohorts;

  • Phase 2 Cohort 1 (1L Unfit AML Mag + Ven + Aza)
  • Phase 2 Cohort 2 (R/R AML Mag + MEC)
  • Phase 2 Cohort 3 (Post-chemo Maintenance Mag + CC-486)

Cycle length is 28 days for both the Safety Run-in and Phase 2 cohorts.

Note: Currently, this study is only open to enrollment into Phase 2 Cohort 2 and Safety Run-in Cohort 3. All other cohorts are closed to screening and enrollment.

Condition Myeloid Malignancies
Treatment cytarabine, etoposide, Mitoxantrone, Azacitidine, CC-486, venetoclax, Magrolimab
Clinical Study IdentifierNCT04778410
SponsorGilead Sciences
Last Modified on22 September 2023

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note